Clinical trials: Diabetes type1
Diabetes Mellitus Type 1 and 2, Diabetes Mellitus Complications
Study to Assess Pharmacodynamics of RM-131 in Patients With Diabetic Gastroparesis
The purpose of this study is to evaluate the pharmacodynamic (PD) and pharmacokinetic (PK) profile and the safety and tolerability of RM-131 in patients with diabetes mellitus and delayed gastric emptying.
- Conditions
- Diabetes Mellitus Type 1 and 2, Diabetes Mellitus Complications, Gastroparesis, Gastrointestinal Motility Disorder
- Trial name
- NCT01394055
- Testing
- RM-131
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Motus Therapeutics, Inc.
Type 1 Diabetes Mellitus
INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes
INHALE-1st is a Phase 2, single-arm, multi-center, clinical study evaluating the safety and efficacy of Afrezza in combination with subcutaneously-injected basal insulin (BI) for youth 6 to <18 years old with newly diagnosed…
- Trial name
- INHALE-1st (NCT07224321)
- Testing
- Technosphere Insulin, Basal insulin
- Where
- 10 sites in United States
- Volunteers
- 100 people
- Sponsor
- Mannkind Corporation
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Single Dose and 34-Day Tolerance Study of INGAP Peptide in Insulin Deficient Patients
The purpose of this study is to evaluate the safety and tolerability of single and multiple doses of intramuscular INGAP Peptide given for the first time in humans as a potential treatment for diabetes.
- Trial name
- NCT00034255
- Testing
- INGAP Peptide
- Where
- 4 sites in United States
- Volunteers
- 62 people
- Sponsor
- GMP Endotherapeutics
Diabetes Mellitus, Type 1
Study of the Long-Term Safety of Pramlintide in Subjects With Type 1 Diabetes Mellitus
This is a multicenter, open-label extension study designed to examine the long-term safety of pramlintide treatment in subjects with type 1 diabetes who have successfully completed treatment in the parent study 137-150.
- Trial name
- NCT00107107
- Testing
- pramlintide acetate
- Where
- 25 sites in United States
- Volunteers
- 190 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 1
A Study of LY3532226 in Participants With Type 1 Diabetes Mellitus
The main purpose of this study is to evaluate the response of glucagon to insulin-induced low blood sugar after administration of the study drug LY3532226 in participants with type 1 diabetes mellitus (T1DM).
- Trial name
- NCT05887999
- Testing
- LY3532226
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Eli Lilly and Company
Chronic Kidney Diseases, Type 1 Diabetes Mellitus
Renal Autologous Cell Therapy (REACT) in Subjects With Type 1 or 2 Diabetes and Chronic Kidney Disease (REGEN-007)
The purpose of this study is to assess the safety, efficacy, and durability of up to two Renal Autologous Cell Therapy (REACT) / rilparencel injections delivered percutaneously into biopsied and non-biopsied contralateral kidneys…
- Conditions
- Chronic Kidney Diseases, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
- Trial name
- NCT05018416
- Testing
- Renal Autologous Cell Therapy (REACT)
- Where
- 5 sites in United States
- Volunteers
- 53 people
- Sponsor
- Prokidney
Diabetes, Diabetes Mellitus, Type 1
A Comparison of Postprandial Glucose After a MMTT, and the Metabolic Effects of Insulin Withdrawal in a Crossover Study in Subjects With Type 1 Diabetes
This is an inpatient treatment, double-blind, randomized, 3-way crossover study in T1DM subjects using insulin pump therapy.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Type1diabetes, Diabetes Mellitus
- Trial name
- NCT04956263
- Testing
- YG1699, Dapagliflozin
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Youngene Therapeutics Inc., Ltd.
Diabetics Mellitus Type 1, Diabetes Mellitus Type 2
Testing the Effect of the InsuPad Device in Daily Life Conditions
This is the test protocol for the InsuPad device. The aim of the study is to show economical benefit when using the InsuPad device, by testing the effect of the InsuPad device on reducing injected insulin dose while keeping the…
- Trial name
- NCT01594801
- Testing
- InsuPad
- Where
- 9 sites in Germany
- Volunteers
- 145 people
- Sponsor
- Insuline Medical Ltd.
Diabetes Mellitus, Type 1
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
The purpose of this study is to find out if baricitinib can delay the onset of clinical type 1 diabetes (T1D) in people who are at high risk to develop T1D. Participation in the study will last up to approximately 5 years.
- Trial name
- BARICADE-DELAY (NCT07222137)
- Testing
- Baricitinib
- Where
- 112 sites in United States, Australia and 17 more
- Volunteers
- 150 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes Mellitus
Phase II Pharmacokinetics Study of Humalog and Humulin-R With and Without rHuPH20 in Type 1 Diabetes Mellitus
Humalog and Humulin-R (recombinant human insulin) are Food and Drug Administration (FDA) approved medications for the treatment of diabetes mellitus.
- Trial name
- NCT00774800
- Testing
- Humalog, Humulin-R, Recombinant human hyaluronidase PH20 (rHuPH20)
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Halozyme Therapeutics
Type 1 Diabetes Mellitus
A Study of How Insulin Peglispro (LY2605541) and Insulin Glargine Affect the Breakdown of Fat and Sugar in Type 1 Diabetics
This is a two-period study of participants with type 1 diabetes mellitus (T1DM). In each period, participants will receive once daily injections of stable dose LY2605541 or insulin glargine for 28 to 35 days followed by…
- Trial name
- NCT01925989
- Testing
- LY2605541, Insulin Glargine
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1
INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes
INHALE-3 is a Phase 4, randomized controlled trial (RCT) that will randomly assign participants ≥18 years of age with type 1 diabetes (T1D) using multiple daily injections (MDI), an automated insulin delivery (AID) system, or a…
- Trial name
- NCT05904743
- Testing
- Afrezza, insulin degludec, Rapid-acting Insulin Analog
- Where
- 19 sites in United States
- Volunteers
- 141 people
- Sponsor
- Mannkind Corporation
Diabetes Mellitus, Type 1
Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3)
The study will investigate the efficacy, safety, tolerability and Pharmacokinetic(PK) of 3 doses of empagliflozin compared with placebo over 26 weeks in 960 patients with type 1 diabetes mellitus as adjunctive therapy to insulin
- Trial name
- NCT02580591
- Testing
- Empagliflozin
- Where
- 189 sites in United States, Australia and 22 more
- Volunteers
- 977 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Diabetes Mellitus, Type 1
PROMISE Study: An Evaluation of an Implantable Continuous Glucose Sensor up to 180 Days
The purpose of this clinical investigation is to evaluate the accuracy of the Eversense® continuous Glucose Monitoring System (Eversense® 180 CGM System) measurements when compared with reference standard measurements up to 180…
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- PROMISE (NCT03808376)
- Testing
- Continuous Glucose Monitoring System
- Where
- 8 sites in United States
- Volunteers
- 208 people
- Sponsor
- Senseonics, Inc.
Diabetes Mellitus, Type 1
General Use-results Surveillance With Awiqli in Patients With Diabetes Mellitus
The purpose of the study is to investigate the safety and effectiveness of Awiqli in participants with diabetes mellitus under real world clinical practice in Japan. Participants will get Awiqli as prescribed by the study doctor.
- Trial name
- NCT06807190
- Testing
- Insulin Icodec
- Where
- 116 sites in Japan
- Volunteers
- 630 people
- Sponsor
- Novo Nordisk A/S